These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28356598)

  • 21. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved Therapeutic Window in
    Zhong H; Chen C; Tammali R; Breen S; Zhang J; Fazenbaker C; Kennedy M; Conway J; Higgs BW; Holoweckyj N; Raja R; Harper J; Pierce AJ; Herbst R; Tice DA
    Mol Cancer Ther; 2019 Jan; 18(1):89-99. PubMed ID: 30352801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by
    Cheng LJ; Wong G; Chay WY; Ngeow J; Tan Y; Soon SS; Aziz MIA; Pearce F; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):441-448. PubMed ID: 33593205
    [No Abstract]   [Full Text] [Related]  

  • 24. PARP inhibitors in BRCA mutation-associated ovarian cancer.
    Clamp A; Jayson G
    Lancet Oncol; 2015 Jan; 16(1):10-2. PubMed ID: 25481790
    [No Abstract]   [Full Text] [Related]  

  • 25. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
    Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
    Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R; Gourley C
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R
    Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP Inhibitors for Cancer Therapy.
    Lin KY; Kraus WL
    Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases.
    Kasherman L; Madariaga A; Rouzbahman M; Murphy K; Shultz D; Stockley T; Oza AM
    Int J Gynecol Cancer; 2021 Jan; 31(1):139-143. PubMed ID: 32998861
    [No Abstract]   [Full Text] [Related]  

  • 35. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
    McCann KE
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):12-17. PubMed ID: 30540581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance olaparib in advanced ovarian cancer.
    Burki TK
    Lancet Oncol; 2018 Dec; 19(12):e671. PubMed ID: 30509885
    [No Abstract]   [Full Text] [Related]  

  • 38. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365755
    [No Abstract]   [Full Text] [Related]  

  • 39. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
    Barber LJ; Sandhu S; Chen L; Campbell J; Kozarewa I; Fenwick K; Assiotis I; Rodrigues DN; Reis Filho JS; Moreno V; Mateo J; Molife LR; De Bono J; Kaye S; Lord CJ; Ashworth A
    J Pathol; 2013 Feb; 229(3):422-9. PubMed ID: 23165508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
    Veeck J; Ropero S; Setien F; Gonzalez-Suarez E; Osorio A; Benitez J; Herman JG; Esteller M
    J Clin Oncol; 2010 Oct; 28(29):e563-4; author reply e565-6. PubMed ID: 20679605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.